Sp626
PRESENTATION OF CLINICAL PRACTICE (CP) SECTION RESEARCH MENTOR AWARD: ROBERT (ROCKY) E. SCHOEN, MD, MPH
Date
May 19, 2024
Tracks
Related Products
THE TISSUE SYSTEMS PATHOLOGY TEST ENABLES RISK-ALIGNED MANAGEMENT FOR PATIENTS WITH BARRETT’S ESOPHAGUS
INTRODUCTION: The goal of Barrett’s esophagus (BE) surveillance is to detect dysplasia and esophageal adenocarcinoma (EAC) at early, treatable stages…
INCREASED REFLUX SECONDARY BILE ACIDS ARE ASSOCIATED WITH SHIFTS TO THE MICROBIOME AND TRANSCRIPTOME IN BARRETT’S ESOPHAGUS
Background: Bile acids comprise a major component of refluxate in GERD, the major risk factor for Barrett’s esophagus (BE) and esophageal adenocarcinoma (EAC). Bile acids are metabolized by bacteria, and bacterial composition is also impacted by exposure to bile acids…